Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future
- 14 October 2016
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Immunology
- Vol. 13 (3), 223-233
- https://doi.org/10.1080/1744666x.2017.1243468
Abstract
Introduction: Anti TNF-α agents have become a significant advance in the management of ulcerative colitis, proving to induce, with rapid onset, clinical and endoscopic remission. However, there is still a considerable unmet medical need in ulcerative colitis. Areas covered: The aim of this review was to summarize the patterns of use and the effectiveness of anti TNF-α in ulcerative colitis, highlighting their current position in treatment algorithms. Moreover, we set out a five-year view hypothesizing different treatment strategies. Expert commentary: The rapid onset of action and the effectiveness in inducing mucosal healing are the most important pros of anti TNF-α, supporting present and future use. Conversely, the relevant risk of loss of response and the safety profile have raised several concerns. In the future, the advent of different molecular targeting therapies can improve the management of UC patients, evolving to individually tailored strategies.Keywords
This publication has 95 references indexed in Scilit:
- Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)Scandinavian Journal of Gastroenterology, 2015
- Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future DirectionsClinical Gastroenterology and Hepatology, 2015
- Clinical Predictors of Colectomy in Patients with Ulcerative Colitis: Systematic Review and Meta-analysis of Cohort StudiesJournal of Crohn's and Colitis, 2014
- Infliximab in Steroid-dependent Ulcerative ColitisInflammatory Bowel Diseases, 2013
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current managementJournal of Crohn's and Colitis, 2012
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosisJournal of Crohn's and Colitis, 2012
- A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and HospitalizationThe American Journal of Gastroenterology, 2010
- Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or InfliximabGastroenterology, 2009
- Long-term outcome after infliximab for refractory ulcerative colitisJournal of Crohn's and Colitis, 2008
- Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2008